Ipafricept: Phase Ib data

Top-line data from 17 evaluable patients with recurrent platinum-sensitive ovarian cancer in an open-label, dose-escalation, U.S. Phase Ib trial showed

Read the full 204 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE